ARZ.TO : Summary for ARALEZ PHARMACEUTICALS INC - Yahoo Finance

U.S. Markets closed

Aralez Pharmaceuticals Inc. (ARZ.TO)


Toronto - Toronto Delayed Price. Currency in CAD
Add to watchlist
5.58-0.14 (-2.45%)
At close: 3:01PM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.72
Open5.69
Bid5.56 x
Ask5.69 x
Day's Range5.38 - 5.69
52 Week Range4.07 - 8.75
Volume6,507
Avg. Volume13,406
Market Cap365.08M
Beta0.81
PE Ratio (TTM)-3.33
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield0.00 (0.00%)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire6 days ago

    Aralez Announces Issuance Of Additional U.S. Patent For Yosprala

    MISSISSAUGA, Ontario, Jan. 11, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO), a global specialty pharmaceutical company, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent entitled "Compositions and Methods for Delivery of Omeprazole Plus Acetylsalicylic Acid" that covers Yosprala™ (aspirin and omeprazole), the only prescription fixed-dose combination of an anti-platelet agent, aspirin, and the proton pump inhibitor, omeprazole, in the U.S. The USPTO issued U.S. Patent number 9,539,214 on January 10, 2017, which will expire in late 2032 with possible patent term adjustment into early 2033. Aralez plans to list this patent in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book.  Once listed there will be a total of four patents in the Orange Book for Yosprala.

  • PR Newswire8 days ago

    Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040

    MISSISSAUGA, Ontario, Jan. 9, 2017 /PRNewswire/ -- Aralez Pharmaceuticals Inc. (ARLZ) (ARZ.TO) ("Aralez" or the "Company") today announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its investigational candidate, PA10040, for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. "As we seek to maximize the opportunity for Yosprala on a worldwide basis, we plan to engage in early discussions with potential partners for territories outside of the United States and Canada," said Adrian Adams, Chief Executive Officer of Aralez. Aspirin and omeprazole is currently marketed in a tablet form under the brand name Yosprala™ in the United States and indicated for patients who require aspirin for secondary prevention of CV and cerebrovascular events and who are at risk of developing aspirin-associated gastric ulcers.

  • CNW Group8 days ago

    Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040

    Aralez Submits Marketing Authorization Application To The European Medicines Agency For PA10040